Takeda's buy rating reaffirmed due to drug approvals, strong pipeline, and global presence.

Takeda, a major Japanese pharmaceutical company, has had its prior buy rating reaffirmed. Positive factors supporting this rating include recent drug approvals, a robust future drug development pipeline, global market reach, and an investment-grade credit rating. The company serves multiple clinical areas by addressing specific medical needs. However, investors should be aware of sector risks such as regulatory challenges and earnings volatility that could impact performance.

Takeda Pharmaceutical's shares are trading at USD 18.56 on Pluang, showing a slight decline of 0.64% as of Oct 14, 2026 03:02 WIB. The stock has a dividend yield of 3.3% and a market cap of $58.84 billion, reflecting its strong position in the health sector.